Navigation Links
REACT clinical trial supports new approach of accelerated treatment for Crohn's disease

The final results from an international clinical trial involving nearly 2,000 patients with Crohn's disease support the use of a new management strategy referred to as accelerated step-care as a best practice for the care of active Crohn's disease. The REACT (Randomized Evaluation of an Algorithm for Crohn's Treatment) study, led by Robarts Clinical Trials at Western University (London, Canada) provides valuable new insights for community gastroenterologists which should benefit patients. The results of the study will be presented at the European Crohn's and Colitis Organisation (ECCO) annual congress taking place in Copenhagen, Denmark on February 20-22, 2014.

Crohn's disease is a chronic, potentially debilitating, condition of the gastrointestinal tract which can cause abdominal pain, diarrhea, vomiting, and weight loss among other symptoms. Well over five million people globally are affected by Crohn's disease and ulcerative colitis.

Dr. Brian Feagan, CEO and Senior Scientific Director of Robarts Clinical Trials and a professor in the Division of Gastroenterology at Western's Schulich School of Medicine & Dentistry, says the medical management of Crohn's disease has undergone important changes over the past two decades with the introduction of TNF antagonists such as adalimumab and infliximab. The current treatment approach features sequential and incremental treatment intensification based on symptoms. In contrast, an accelerated step-care approach involves the early introduction of combined immunosuppression in high risk patients, which has been shown to induce and maintain remission, reduce the use of corticosteroids, and heal intestinal ulceration in those who fail conventional treatment.

Subsequent research, performed in both Crohn's disease and rheumatoid arthritis, indicated that TNF antagonists work best when: 1) used in combination with antimetabolites (e.g., azathioprine, methotrexate) and 2) introduced early in the course of the disease. Controlled studies such as CHARM (Crohn's Trial of the Fully Human Antibody Adalimumab for Remission Maintenance) have also demonstrated that TNF antagonist-based regimens can reduce the rate of surgery and hospitalization in comparison to conventional therapy.

"However, adoption of these key concepts by community gastroenterologists has been relatively slow," says Dr. Feagan. "This is primarily because many believe that the safety and efficacy of these agents may not be generalizable to their individual practice, since they were tested in academic centers. The REACT study was designed to address these concerns."

In this cluster-randomized trial, 39 community gastroenterology practices in Canada or Belgium were randomly assigned to a conventional management approach or to an accelerated step-care algorithm that featured early use of combined adalimumab/antimetabolite therapy. Within practices, up to 60 consecutive patients were entered and evaluated for 24 months to determine whether the implementation of an accelerated step-care approach would improve the management of Crohn's disease in comparison to conventional management methods.

Final results from the REACT clinical trial showed the proportion of patients in remission at 12 months was marginally greater in the group assigned to accelerated step-care. However, significant and clinically important reduction in rates for hospitalization, complications and surgeries were observed in practices assigned to early combined immunosuppression up to 24 months.

The study reached several important conclusions:

  • Early introduction of combined therapy in the community may be both feasible and safe
  • Use of this paradigm may be more effective than conventional management for the prevention of diseaserelated complications, surgeries and hospitalizations
  • Reliance on symptoms exclusively to guide therapy may be a sub-optimal management strategy


Contact: Kathy Wallis
519-661-2111 x81136
University of Western Ontario

Related medicine news :

1. Reactions to HIV drug have autoimmune cause, reports AIDS journal
2. Viewers family background affects how they react to MTV shows 16 and Pregnant, Teen Mom
3. Newly Aggressive Dogs May Be Reacting to Pain
4. Genes May Influence Reactions to Painkillers
5. New anti-inflammatory drugs pinch off reactive oxygen species at the source
6. Study identifies causes for high rates of allergic reactions in children with food allergies
7. Rate of severe reactions higher than thought in young children with food allergies
8. Chronic Pain May Depend on Emotional Reaction to Injury
9. Global platelet reactivity and high risk ACS patients
10. Global platelet reactivity identifies high risk ACS patients
11. Womens Brains React Differently Than Mens to Alcoholism, Study Finds
Post Your Comments:
Related Image:
REACT clinical trial supports new approach of accelerated treatment for Crohn's disease
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... solution provider of IBM software products, introduced a new company, RightSensor™ LLC, an ... and data communications capability. RightSensor™ provides a fully-managed approach for customers requiring ...
(Date:10/13/2015)... ... 13, 2015 , ... Dr. Poneh Ghasri, dentist in West Hollywood , ... The research, which was conducted at the Dental Institute at King's College London in ... stress during pregnancy and future dental health in the child. For years, researchers have ...
(Date:10/13/2015)... ... October 13, 2015 , ... A child without a healthy mouth is ... the leading remote invisible aligner system, has joined with Global Dental Relief ... For each aligner treatment plan purchased, SmileCareClub will donate one clinic visit to a ...
(Date:10/13/2015)... Hills, CA (PRWEB) , ... October 13, 2015 ... ... management and workflow solutions, announced today their Title Sponsorship of Synergy 2015. The ... in Henderson, NV at Green Valley Ranch and will unite customers, partners, WennSoft ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... Illinois with more than 59,000 emergency department visits per year, today announced the ... T-System, to help improve clinical, operational and financial outcomes. , In ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 2015  Kay Elledge, M.D., an established South ... of Obstetrics and Gynecology (FACOG) for the past ... Genuine Self Medical Laser Center where she provides ... of Breast Cancer Awareness Month , the ... MonaLisa Touch treatments initiated in the month ...
(Date:10/13/2015)... 13, 2015  Human Longevity, Inc. (HLI), the genomics-based, ... announced today the launch of the company,s first Health ... the potential to transform healthcare. The inaugural Health Nucleus ... , at HLI,s headquarters facility. More Health Nucleus facilities ... and International cities. --> ...
(Date:10/13/2015)... SAN DIEGO , Oct. 13, 2015 /PRNewswire/ ... bioelectronics for use in research and diagnostics, announces ... of $1.6 million led by Serra Ventures. ... Nanomed,s mission is providing low-cost, easy-to-use monitoring and ... personal health decisions. The funding round will enable ...
Breaking Medicine Technology: